AVROBIO Inc
NASDAQ:TECX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sampyo Cement Co Ltd
KOSDAQ:038500
|
KR |
|
Chord Energy Corp
NASDAQ:CHRD
|
US |
|
A
|
Audax Renovables SA
XBER:54F
|
ES |
|
Emerge Gaming Ltd
ASX:EM1
|
AU |
|
Fu Shou Yuan International Group Ltd
HKEX:1448
|
CN |
|
HELMA Eigenheimbau AG
XETRA:H5E
|
DE |
|
A
|
Anuh Pharma Ltd
BSE:506260
|
IN |
|
E
|
Edelteq Holdings Bhd
KLSE:EDELTEQ
|
MY |
|
PuraPharm Corp Ltd
HKEX:1498
|
HK |
|
N
|
Novarex Co Ltd
KOSDAQ:194700
|
KR |
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
CA |
|
Omda AS
OSE:OMDA
|
NO |
|
F
|
Filatex India Ltd
NSE:FILATEX
|
IN |
|
Genius Metals Inc
XTSX:GENI
|
CA |
|
Balkan Mining and Minerals Ltd
ASX:BMM
|
AU |
|
Hancock Whitney Corp
NASDAQ:HWC
|
US |
|
DP Poland PLC
LSE:DPP
|
UK |
|
I
|
ISC Fresh Water Investment SOCIMI SA
MAD:YISC
|
ES |
AVROBIO Inc
Research & Development
AVROBIO Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AVROBIO Inc
NASDAQ:TECX
|
Research & Development
-$62.5m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
AVROBIO Inc
Glance View
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of five lentiviral-based gene therapy programs, which include AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3, and AVR-RD-03 for the treatment of Pompe disease.
See Also
What is AVROBIO Inc's Research & Development?
Research & Development
-62.5m
USD
Based on the financial report for Dec 31, 2025, AVROBIO Inc's Research & Development amounts to -62.5m USD.
What is AVROBIO Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-36%
Over the last year, the Research & Development growth was -56%. The average annual Research & Development growth rates for AVROBIO Inc have been -36% over the past three years .
